RxDoctor Payments Data

Charles Moore, MD

Otolaryngology · New Iberia, LANPI 1417319807

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (59.7%), travel and lodging and education — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by Inspire Medical Systems, Inc. at 41.9% of the total. Reporting peaked in 2024 at $1,976 and has fallen 68.7% since, to $618 in 2025.

$6,015in general payments, 2019–2025

Across 80 payments — averaging $75.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inspire Medical Systems, Inc.$3K
  • Medical Device Business Services, Inc.$648
  • Stryker$614
  • Medtronic$424
  • Acclarent, Inc$305
  • Sanofi$270
  • plus $1K from 14 others

What the payments were for

  • Travel & lodging$1,31922%
  • Food & beverage$3,59060%
  • Education$1,10618%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,015 in reported general payments places this provider in the 85th percentile of 218 otolaryngology providers in Louisiana.

See all otolaryngology providers in Louisiana

Medicare billing

Part B allowed, 2024
$237,150
Medicare patients
395
Services billed
3,867

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab12$46,786
Azelastine Hcl279$8,232
Ipratropium Bromide220$6,753
Fluticasone Propionate313$4,222
Ofloxacin62$1,729
Fluocinolone Acetonide Oil17$899
Prednisolone Acetate19$818
Cefdinir49$740
Famotidine67$507
Mupirocin69$478
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav43$447
Omeprazole50$304
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen36$249
Methylprednisolone25$144
Montelukast Sodium21$132

Paid to pharmacies, not to this prescriber.

Other otolaryngology in New Iberia

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →